The 10th International Conference on Alzheimer's Disease Drug Discovery was presented by the Alzheimer's Drug Discovery Foundation (ADDF), the only public charity solely dedicated to rapidly accelerating the discovery and development of drugs to prevent, treat and cure Alzheimer's disease and cognitive aging.  This conference brought together academic and industry scientists to accelerate the development of novel drug discovery programs for Alzheimer’s disease and related dementias.

I. Neuroprotection & Prevention

Chair: Frank Longo, MD, PhD, Stanford University

II. Anti-Amyloid & Protein Misfolding

Chair: Michael Wolfe, PhD, Brigham and Women's Hospital

III. Anti-Tangles & Frontotemporal Dementia

Chair: Jeff Kuret, PhD, Ohio State University

IV. Alternative Strategies: New Targets for ALZHEIMER'S DISEASE Therapy

Chair: Diana Shineman, PhD, Alzheimer’s Drug Discovery Foundation

Plenary Talk: Bridging Neurocognitive Aging and Disease Modification: Targeting Functional Mechanisms of Impairment

Michela Gallagher, PhD, Johns Hopkins University

Plenary Talk: TDP-43 as a New Target for Neurodegenerative Disease

Virginia Lee, PhD, MBA, University of Pennsylvania

Click below to read the conference summary authored by Dr. Diana Shineman, ADDF's Director of Scientific Affairs. 

The 2009 edition of this conference attracted attendees from around the globe.  Attendees included:

- Academic and industry scientists engaged in drug discovery research for neurodegenerative diseases or CNS

- Business development and licensing professionals

- Alliance management professionals

- Venture capitalists and other investors.

Review program, speakers, supporters of the 9th International Conference on Alzheimer's Drug Discovery held last year in New York City.